Indegene Supports a Global Pharma Company with Cost-Effectiveness Analysis of Oncology Drug vs. Biosimilars
Indegene Supports a Global Pharma Company with Cost-Effectiveness Analysis of Oncology Drug vs. Biosimilars
2 PagesA leading global biopharmaceutical company needed to evaluate its oncology drug's cost-effectiveness against two biosimilars for myelosuppressive chemotherapy patients with early-stage breast cancer and non-Hodgkin's lymphoma, requiring data gap solutions with extrapolated modeling and sensitivity testing. Indegene's advanced analytics software bridged real-world data limitations through sophisticated extrapolation algorithms, robust sensitivity analyses, and integrated modeling tools, delivering defensible, accurate cost-effectiveness insights that strengthened market positioning and informed strategic decisions with reliable, comprehensive economic evidence.
